Sichuan Huiyu Pharmaceutical Co Ltd (688553) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has a cash flow conversion efficiency ratio of 0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥58.54 Million ≈ $8.57 Million USD) by net assets (CN¥3.72 Billion ≈ $544.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688553 market cap overview for the company's overall valuation and market capitalisation.
Sichuan Huiyu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Sichuan Huiyu Pharmaceutical Co Ltd (688553) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ruitai Materials Technology Co Ltd
SHE:002066
|
-0.153x |
|
Shenzhen Absen Optoelectronic Co Ltd
SHE:300389
|
0.210x |
|
WESTROCK COFFEE CL.A
F:V3J
|
0.135x |
|
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
|
N/A |
|
Vats Liquor Chain Store Management Joint Stock Co Ltd
SHE:300755
|
0.146x |
|
Advanced Wireless Semiconductor Co
TWO:8086
|
0.035x |
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
0.028x |
Annual Cash Flow Conversion Efficiency for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. View Sichuan Huiyu Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.97 Billion ≈ $581.43 Million |
CN¥242.96 Million ≈ $35.55 Million |
0.061x | +244.81% |
| 2023-12-31 | CN¥3.77 Billion ≈ $552.32 Million |
CN¥66.93 Million ≈ $9.79 Million |
0.018x | -66.02% |
| 2022-12-31 | CN¥3.72 Billion ≈ $544.07 Million |
CN¥194.06 Million ≈ $28.40 Million |
0.052x | -58.39% |
| 2021-12-31 | CN¥3.56 Billion ≈ $520.72 Million |
CN¥446.36 Million ≈ $65.32 Million |
0.125x | -75.70% |
| 2020-12-31 | CN¥751.48 Million ≈ $109.97 Million |
CN¥387.95 Million ≈ $56.77 Million |
0.516x | -35.33% |
| 2019-12-31 | CN¥408.65 Million ≈ $59.80 Million |
CN¥326.22 Million ≈ $47.74 Million |
0.798x | +193.22% |
| 2018-12-31 | CN¥-150.70 Million ≈ $-22.05 Million |
CN¥129.06 Million ≈ $18.89 Million |
-0.856x | -1305.63% |
| 2017-12-31 | CN¥-185.32 Million ≈ $-27.12 Million |
CN¥-13.16 Million ≈ $-1.93 Million |
0.071x | -- |
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more